At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed papillary or follicular thyroid carcinoma, differentiated, with metastatic disease documented by imaging
- ✓All metastatic disease foci ≤10 mm in all dimensions
- ✓Prior total or near-total thyroidectomy AND at least 1 course of radioiodine (≥29.9 mCi) OR demonstrated negative uptake on postoperative low-dose scan
- ✓Whole body radioiodine scan within 1-3 days demonstrating no visible iodine uptake in lesions, OR negative uptake on postoperative low-dose scan within past 12 weeks
- ✕Known brain metastases
- ✕Prior cytotoxic chemotherapy for thyroid cancer
- ✕Concurrent combination antiretroviral therapy for HIV-positive patients
- ✕Other concurrent anticancer therapy or investigational agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
In Brief
A Phase 2 clinical trial evaluating Decitabine, Iodine I 131, and 3 other interventions for Recurrent Thyroid Cancer and 6 related conditions. Completed, enrolled 12 participants across 3 sites.
Detailed Summary
This phase II trial is studying how well decitabine works in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer that has stopped responding to radioactive iodine. Iodine I 131 (radioactive iodine) kills thyroid cancer cells. Metastatic thyroid cancer cells can lose the ability to be treated with radioactive iodine. Decitabine may help thyroid cancer cells regain the ability to respond to treatment with radioactive iodine.
Study Details
Timeline
Interventions
Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
Undergo thyrotropin-alfa stimulated radioactive iodine scan
Undergo thyrotropin-alfa stimulated radioactive iodine scan
Optional correlative studies
Optional correlative studies